Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (131-140 of 157) with videos related to

Pageof 16
Sort By:
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 TrialEric Lawitz, Nancy Reau, Federico Hinestrosa, et al.
Annals of Hepatology|October 15, 2016
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infectionMaribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, et al.
Gastroenterology|October 16, 2013
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapyNezam H Afdhal, Geoffrey M Dusheiko, Edoardo G Giannini, et al.
Gastroenterology|November 5, 2013
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infectionGregory T Everson, Karen D Sims, Maribel Rodriguez-Torres, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trialsEvguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, et al.
Lancet (London, England)|March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trialKris V Kowdley, Eric Lawitz, Israel Crespo, et al.
Lancet (London, England)|August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyEric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisMichael P Curry, Jacqueline G O'Leary, Natalie Bzowej, et al.
Journal of Hepatology|January 11, 2025
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trialsJavier Armisen, Mitra Rauschecker, Janeli Sarv, et al.
The New England Journal of Medicine|June 24, 2011
Telaprevir for retreatment of HCV infectionStefan Zeuzem, Pietro Andreone, Stanislas Pol, et al.
Pageof 16

Showing results (131-140 of 157) with videos related to

Sort By:
Pageof 16
Gastroenterology|August 4, 2016
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 TrialEric Lawitz, Nancy Reau, Federico Hinestrosa, et al.
Annals of Hepatology|October 15, 2016
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infectionMaribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, et al.
Gastroenterology|October 16, 2013
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapyNezam H Afdhal, Geoffrey M Dusheiko, Edoardo G Giannini, et al.
Gastroenterology|November 5, 2013
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infectionGregory T Everson, Karen D Sims, Maribel Rodriguez-Torres, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 1, 2014
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trialsEvguenia S Svarovskaia, Hadas Dvory-Sobol, Neil Parkin, et al.
Lancet (London, England)|March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trialKris V Kowdley, Eric Lawitz, Israel Crespo, et al.
Lancet (London, England)|August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyEric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
The New England Journal of Medicine|November 17, 2015
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated CirrhosisMichael P Curry, Jacqueline G O'Leary, Natalie Bzowej, et al.
Journal of Hepatology|January 11, 2025
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trialsJavier Armisen, Mitra Rauschecker, Janeli Sarv, et al.
The New England Journal of Medicine|June 24, 2011
Telaprevir for retreatment of HCV infectionStefan Zeuzem, Pietro Andreone, Stanislas Pol, et al.
Pageof 16